ServiceNow, Vertex Pharmaceuticals And More: CNBC's 'Final Trades'

Benzinga

10/03

On CNBC's “Halftime Report Final Trades,” on Thursday, Jason Snipe, founder and chief investment officer of Odyssey Capital Advisors, said he likes ServiceNow, Inc. (NYSE:NOW), which is down 14% year-...

网页链接

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2572507249"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2572507249\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2572507249?lang=zh_CN&edition=fundamental","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/10/03/Crypto-Trader-Investor-Broker-Using-Smar.jpeg?optimize=medium&dpr=2&auto=webp&width=260","is_english":true,"pubTime":"2025-10-03 20:23","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2572507249","market":"nz","top_or_hot":-1,"title":"ServiceNow, Vertex Pharmaceuticals And More: CNBC's 'Final Trades'","media":"Benzinga","content":"<div>\n<p>On CNBC's “Halftime Report Final Trades,” on Thursday, Jason Snipe, founder and chief investment officer of Odyssey Capital Advisors, said he likes ServiceNow, Inc. (NYSE:NOW), which is down 14% year-...</p>\n\n<a href=\"https://www.benzinga.com/trading-ideas/long-ideas/25/10/48014266/servicenow-vertex-pharmaceuticals-and-more-cnbcs-final-trades\">网页链接</a>\n\n</div>\n","source":"benzinga_hot_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ServiceNow, Vertex Pharmaceuticals And More: CNBC's 'Final Trades'</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nServiceNow, Vertex Pharmaceuticals And More: CNBC's 'Final Trades'\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-10-03 20:23 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/trading-ideas/long-ideas/25/10/48014266/servicenow-vertex-pharmaceuticals-and-more-cnbcs-final-trades><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>On CNBC's “Halftime Report Final Trades,” on Thursday, Jason Snipe, founder and chief investment officer of Odyssey Capital Advisors, said he likes ServiceNow, Inc. (NYSE:NOW), which is down 14% year-...</p>\n\n<a href=\"https://www.benzinga.com/trading-ideas/long-ideas/25/10/48014266/servicenow-vertex-pharmaceuticals-and-more-cnbcs-final-trades\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0719512351.SGD","symbol_name":"JPMorgan Funds - US Technology A (acc) SGD","start_time":0,"source_url":"https://www.benzinga.com/trading-ideas/long-ideas/25/10/48014266/servicenow-vertex-pharmaceuticals-and-more-cnbcs-final-trades","article_id":"2572507249","we_media_id":null,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/10/03/Crypto-Trader-Investor-Broker-Using-Smar.jpeg?optimize=medium&dpr=2&auto=webp&width=260"],"rights":{"source":"benzinga_hot_news","url":"https://www.benzinga.com/trading-ideas/long-ideas/25/10/48014266/servicenow-vertex-pharmaceuticals-and-more-cnbcs-final-trades","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2572507249","pubTimestamp":1759494180,"columns":[],"sourceInfo":{"source_id":"benzinga_hot_news","name":"Benzinga"},"weMediaInfo":null,"summary":"Jason Snipe likes ServiceNow (NOW), down 14% YTD. Morgan Stanley upgraded to Overweight. Shannon Saccocia chose iShares Core S&P Small-Cap ETF. Jim Lebenthal recommends Vertex Pharmaceuticals (VRTX).","collect":0,"end_time":0,"defaultTopTitle":"benzinga.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0719512351.SGD":"JPMorgan Funds - US Technology A (acc) SGD","IE00BZ9MQY76.HKD":"FTGF CLEARBRIDGE US AGGRESSIVE GROWTH \"A\" (HKD) ACC","SG9999001176.USD":"United Global Healthcare Acc USD","LU0566484027.USD":"安本美国小盘成长股","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU2362541273.HKD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (HKD) ACC","LU0348723411.USD":"ALLIANZ GLOBAL HI-TECH GROWTH \"A\" (USD) INC","LU1951200564.SGD":"Natixis Thematics AI & Robotics Fund R/A SGD","LU0354030438.USD":"富国美国大盘成长基金Cl A Acc","LU2023250843.SGD":"Allianz Thematica Cl AT Acc H2-SGD","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","BK4127":"投资银行业与经纪业","LU2028103732.USD":"ALLIANZ GLOBAL SUSTAINABILITY \"AMG\" (USD) INC","LU1674673691.USD":"HSBC GIF GLOBAL LOWER CARBON EQUITY \"AD\" (USD) INC","LU1720051108.HKD":"ALLIANZ GLOBAL ARTIFICIAL INTELLIGENCE \"AT\" (HKD) ACC","LU0158827781.USD":" ALLIANZ GLOBAL SUSTAINABILITY \"AT\" (USD) ACC","LU1989764748.USD":"东方汇理环球颠覆性机遇A2 Acc","LU0354030511.USD":"ALLSPRING  U.S. LARGE CAP GROWTH \"I\" (USD) ACC","LU0820561909.HKD":"ALLIANZ INCOME AND GROWTH \"AM\" (HKD) INC","LU1988902786.USD":"FULLERTON LUX FUNDS GLOBAL ABSOLUTE ALPHA \"I\" (USD) ACC","LU0316494557.USD":"FRANKLIN GLOBAL FUNDAMENTAL STRATEGIES \"A\" ACC","LU0432979614.USD":"JPM GLOBAL HEALTHCARE \"A\" ACC","LU2458330243.SGD":"FRANKLIN SHARIAH TECHNOLOGY \"A-H1\" (SGDHDG) ACC","BK4613":"AI应用软件","NOW":"ServiceNow","LU1244550221.USD":"FRANKLIN GLOBAL MULTI-ASSET  INCOME \"A\" (USDHEDGED) INC (M)","LU0267386448.USD":"FIDELITY FIRST ALL COUNTRY WORLD \"A\" (USD) INC","LU0082616367.USD":"摩根大通美国科技A（dist）","LU0889565833.HKD":"FRANKLIN TECHNOLOGY \"A\" (HKD) ACC","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","BK4550":"红杉资本持仓","LU0757428866.USD":"THREADNEEDLE (LUX) GLOBAL SMALLER COMPANIES \"AE\" (USD) ACC","LU1244550494.USD":"FRANKLIN GLOBAL MULTI-ASSET INCOME \"A\" (USDHEDGED) ACC","LU2125909759.SGD":"Natixis Thematics Safety H-R/A SGD","LU1162221912.USD":"FRANKLIN INCOME \"A\" (USD) ACC","LU2462157665.USD":"ALLIANZ GLOBAL INCOME \"A\" (USD) INC","LU0011850046.USD":"贝莱德全球长线股票 A2 USD","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","LU1116320901.HKD":"BGF SYSTEMATIC GLOBAL ENHANCED EQUITY YIELD \"A6\" (HKD) INC","BK4607":"DeepSeek概念股","VRTX":"福泰制药","BK4023":"应用软件","VERX":"Vertex, Inc.","LU2063271972.USD":"富兰克林创新领域基金","IE00BMPRXN33.USD":"NEUBERGER BERMAN 5G CONNECTIVITY \"A\" (USD) ACC","LU1363072403.SGD":"Fidelity Global Financial Services A-ACC-SGD","BK4543":"AI","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","LU1559883803.SGD":"Aberdeen Standard SICAV I - North American Smaller Companies Fund A Acc SGD-H","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1"},"translate_title":"ServiceNow、Vertex Pharmaceuticals等：CNBC的“最终交易”","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NOW":1.5,"VERX":1.5,"VRTX":1.5},"content_text":"On CNBC's “Halftime Report Final Trades,” on Thursday, Jason Snipe, founder and chief investment officer of Odyssey Capital Advisors, said he likes ServiceNow, Inc. (NYSE:NOW), which is down 14% year-to-date.\nSupporting his view, Morgan Stanley analyst Keith Weiss upgraded ServiceNow from Equal-Weight to Overweight on Sept. 24, raising the price target from $1,040 to $1,250.\nShannon Saccocia, chief investment officer of NB Private Wealth, named iShares Core S&P Small-Cap ETF (NYSE:IJR) as her final trade.\nDon't forget to check out our premarket coverage here\nJim Lebenthal, partner at Cerity Partners, said Vertex Pharmaceuticals Inc (NASDAQ:VRTX) has a great drug profile here.\nLending support to his choice, Citigroup analyst Geoff Meacham maintained a Buy rating for Vertex Pharmaceuticals on Oct. 2, raising the price target from $550 to $575. The company, on Sept. 25, secured the FDA Breakthrough for Povetacicept in IgAN, completed AMKD trial enrollment, and launched ADPKD study in push for first-in-class kidney therapies.\nPrice Action:\nCheck This Out: \nPhoto: Shutterstock","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}